gene therapy – Benefits Canada.com

Average cost of U.S. health benefits per employee rose 5.2% in 2023: survey

Sadie Janes — Wed, 29 Nov 2023 14:00:32 +0000

The average per-employee cost of U.S. employer-sponsored health benefits has risen by 5.2 per cent in 2023 to reach US$15,797, according to a new survey by Mercer. The survey, which polled more than 1,900 U.S. employers, found cost increases were highest for employers with 50 to 499 employees (7.8 per cent on average) and these […]

The post Average cost of U.S. health benefits per employee rose 5.2% in 2023: survey appeared first on Benefits Canada.com.

Gene, cell therapies raising questions of drug cost responsibilities: expert

Sadie Janes — Fri, 21 Jul 2023 13:00:30 +0000

The growth of gene and cell therapies are raising significant questions among private payers about who bears the responsibility for the costs of these treatments, says Tim Clarke, president at TC Health Consulting Inc. “One issue is whether this is going to be paid for by public health or if it’s an employer health issue. […]

The post Gene, cell therapies raising questions of drug cost responsibilities: expert appeared first on Benefits Canada.com.

2023 Drug Plan Trends Report: How the repercussions of the pandemic are trickling down to drug plans

bwolfe — Fri, 17 Mar 2023 12:56:14 +0000

As the coronavirus pandemic enters its fourth year, it’s perhaps unsurprising that the health crisis has taken its toll on employee mental health. Scotiabank saw a notable rise in claims for mental-health drugs in 2022, says Ayman Alvi, the bank’s vice-president of global pension and benefits, noting the increased use of these medications aligns with […]

The post 2023 Drug Plan Trends Report: How the repercussions of the pandemic are trickling down to drug plans appeared first on Benefits Canada.com.